title: [Salvage thermochemotherapy in advanced refractory malignant tumors in children].
abstract: The data are presented on polychemotherapy given to 17 children with advanced refractory malignant tumors using whole body hyperthermia and hyperglycemia. All patients suffered tumor progression throughout treatment and afterwards. Adjuvant Roncoleukin (interleukin-2) was administered in 5. Such salvage therapy was followed by overall tumor regression in 29.3%. Overall 4-year survival in such cases was 19%. Immunological monitoring of adjuvant whole body hyperthermia and interleukin-2 was carried out.
authors.affiliation: N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Republican Center for Pediatric Oncology and Hematology Research, Minsk, Belarus.
authors.forename: R S
authors.initials: RS
authors.lastname: Ismail-zade
authors.forename: S E
authors.initials: SE
authors.lastname: Buglova
authors.forename: M P
authors.initials: MP
authors.lastname: Potapnev
authors.forename: N V
authors.initials: NV
authors.lastname: Sachivko
authors.forename: A S
authors.initials: AS
authors.lastname: Semenov
authors.forename: V S
authors.initials: VS
authors.lastname: Rud'ko
authors.forename: T V
authors.initials: TV
authors.lastname: Shman
authors.forename: E A
authors.initials: EA
authors.lastname: Zhavrid
mesh_terms: D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D009458:Neuroleptanalgesia; D016879:Salvage Therapy; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D007376:Interleukin-2; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D008558:Melphalan